?B-? stage Non-squmaous NSCLC
Conditions
Interventions
Group A:Pemetrexed 500mg/m2 d1 + CBP AUC=5 d1 q21d
Group B:GEM 1000mg/m2 d1.d8 + CBP AUC=5 d8 q21d
Sponsors
People's hospital of Dongguan, Guangdong Province, China
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Male and female aged 18 years old and over; 2. ECOG PS0-1; 3. Non-squamous NSCLC including adenocarcinoma, bronchioloalveolar carcinoma, large cell carcinoma, undifferential carcinoma, confirmed with histology or cytology, without small cell or squamous component; 4. Initial treatment for advanced non–squamous NSCLC; 5. Expecting life-span, more than twelve weeks; 6. Never have received systemic antitumor treatment before; 7. Have signed the informed consent form; 8. Have evaluating lesions; 9. If with brain metastasis, must without symptoms, such as intracranial hypertension syndrome (nausea, vomit, headache), obstruction in cognition and emotion, epilepsy, lesion-local symptoms; 10. Follow the progress of study and surveillance.
Exclusion criteria
Exclusion criteria: 1. Any unstable systemic diseases (active infection, un-well controlled hypertension, unstable angina, congested heart failure, serious liver or kidney disease, metabolic diseases); 2. Have received systemic antitumor treatment before; 3. Brain metastasis with symptoms; 4. Pregnant female; 5. Hemoglobin less than 8g/dl, or neutrophil leucocytes less than 1.5*10^9/L, platelets less than 75*10^9/L; 6. Serum bilirubin, more than 1.5 times of the upper normal limit. AST and ALT, more than 2 times of the upper normal limit. If excising liver metastasis, AST and ALT, more than 5 times of the upper normal limit; 7. Serum creatinine, more than 1.5 times of the upper normal limit, or creatinine clearance rate less than 50ml/min.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate; | — |
Countries
China
Contacts
Public ContactYun Jia
Outcome results
None listed